Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Notes Payables (2016 - 2024)

Historic Notes Payables for Aytu Biopharma (AYTU) over the last 7 years, with Q4 2024 value amounting to $4.0 million.

  • Aytu Biopharma's Notes Payables rose 29103.31% to $4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.0 million, marking a year-over-year increase of 29103.31%. This contributed to the annual value of $2.4 million for FY2024, which is 5323.1% up from last year.
  • Aytu Biopharma's Notes Payables amounted to $4.0 million in Q4 2024, which was up 29103.31% from $4.3 million recorded in Q3 2024.
  • In the past 5 years, Aytu Biopharma's Notes Payables registered a high of $10.4 million during Q1 2023, and its lowest value of $41318.0 during Q4 2020.
  • Its 4-year average for Notes Payables is $3.2 million, with a median of $2.0 million in 2024.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 8618.93% in 2023, then skyrocketed by 29103.31% in 2024.
  • Aytu Biopharma's Notes Payables (Quarter) stood at $41318.0 in 2020, then soared by 17880.06% to $7.4 million in 2022, then crashed by 86.19% to $1.0 million in 2023, then surged by 291.03% to $4.0 million in 2024.
  • Its Notes Payables was $4.0 million in Q4 2024, compared to $4.3 million in Q3 2024 and $2.4 million in Q2 2024.